ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers

Chairs: P.G. Casali, IT - R.A. Stahel, CH


Rare cancers make up as many as one fifth of all new cancer cases. Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while adult solid rare cancers are hardly grouped together and approached as a collective group of neoplasms. Indeed, they account for as many as 15% of all new cancer cases, thus being the main group within rare cancers. This Course is aimed at dealing with them on an annual basis, to provide the community of clinical oncologists specialising in these tumors with a regular update of recent advances in this specific area. The ultimate goal is to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence.

According to the RARECARE project, which provided a definition and a list of rare cancers, rare adult solid cancers include the following big families of tumors, each of them being therefore covered by a correspondingeducational session within this Course:

• Rare skin cancers and non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Sarcomas
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head and neck cancers

Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment. Thus, this Course will be first offered to clinical oncologists involved into the existing networks covering rare adult solid cancers, with a special attention to the new European Reference Networks due to be created within the EU.

From the educational point of view, one cannot expect that even experienced clinical oncologists are knowledgeable about all these tumors. For this reason, the European Faculty of this Masterclass is asked to focus on the most recent advances, always trying to put them into the context of state-of-the-art treatment of these tumors, with a special view to ESMO Clinical Practice Guidelines.

The course is an ESO-ESMO-RCE joint event
Held in collaboration with
Held under the auspices of

ORGANISING SECRETARIAT
European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax - www.eso.net
Email: raretumours@eso.net


VENUE
Swiss Chamber - Sala Meili
Via Palestro, 2
20121 Milano - Italy
Tel. +39 027632031
www.swisschamber.it


ACCREDITATION
Application for CME recognition will be submitted to Accreditation Council of Oncology in Europe (ACOE), to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system. EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising Secretariat.


BADGE
The badge is the only official evidence of registration and should be worn at all times during the event.


INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the Course. Participants are advised to take out their own personal and travel insurance.


OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.


ACKNOWLEDGEMENT
ESO wishes to express its appreciation to Pharma Mar S.r.l. for having granted free registrations to the course.

IMPORTANT DEADLINES
Travel grants: 30 September 2016
Early registration: 30 September 2016
Late registration: from 1 October 2016

FACULTY
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y. Blay, Centre Léon Bérard, Lyon, FR
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. de Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Lorenzo, European Cancer Patient Coalition, Brussels, BE
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
R. Elisei, Medicina Clinica e Sperimentale, Università di Pisa, IT
N. Fazio, European Institute of Oncology, Milan, IT
S. Ferrari, Istituti Ortopedici Rizzoli, Bologna, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R. Glynne-Jones, Mount Vernon Hospital, Northwood, Middlesex, UK
V. Gregoire, Universitè Catholique, Louvain, BE
S. Grisanti, A.O. Spedali Civili, Brescia, IT
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
D. Lorusso, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Necchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Pica, Proton Therapy Center, Villigen, CH
G. Pravettoni, European Institute of Oncology, Milan, IT
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
S. Rutkowski, University Medical Center Hamburg-Eppendorf, DE
M. Seckl, Hammersmith Campus, London, UK
C. Simon, Université de Lausanne, CHUV Lausanne, CH
R. Soffietti, AOU San Giovanni Battista, Torino, IT
R.A. Stahel, Clinic for Oncology, Zurich, CH
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT

NOVEMBER 25

 NOVEMBER 26

 NOVEMBER 27